Mitigating risk in academic preclinical drug discovery

Area of Science:

• Drug Discovery
• Translational Research
• Academic Research

Background:

• Academic drug discovery centers are increasing, merging academic research with industry preclinical practices.
• Realizing the potential requires academic researchers to understand preclinical drug discovery risks.
• Translational research programs need strong institutional organization and support.

Purpose of the Study:

• To discuss strategies for mitigating risks in academic preclinical drug discovery.
• To guide the effective organization of translational research programs in academic settings.

Main Methods:

• Discussion of risk mitigation strategies.
• Focus on key preclinical drug discovery aspects: organization, target selection, assay design, medicinal chemistry, and preclinical pharmacology.

Main Results:

• Identified key risk areas in academic preclinical drug discovery.
• Proposed strategies to mitigate these risks across various stages of the discovery pipeline.

Conclusions:

• Academic drug discovery centers must address inherent risks for successful translational research.
• Implementing robust organizational and risk management strategies is vital for maximizing the impact of academic drug discovery efforts.